Medy-Tox Inc. (KOSDAQ:086900)
South Korea
· Delayed Price · Currency is KRW 127,100
+500 (0.39%)
At close: Dec 5, 2025
Medy-Tox Revenue
Medy-Tox had revenue of 61.02B KRW in the quarter ending September 30, 2025, with 13.30% growth. This brings the company's revenue in the last twelve months to 241.80B, up 0.14% year-over-year. In the year 2024, Medy-Tox had annual revenue of 228.62B with 3.39% growth.
Revenue (ttm)
241.80B
Revenue Growth
+0.14%
P/S Ratio
3.69
Revenue / Employee
336.76M
Employees
718
Market Cap
892.21B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 228.62B | 7.50B | 3.39% |
| Dec 31, 2023 | 221.12B | 26.02B | 13.34% |
| Dec 31, 2022 | 195.10B | 10.23B | 5.53% |
| Dec 31, 2021 | 184.87B | 44.04B | 31.27% |
| Dec 31, 2020 | 140.83B | -65.07B | -31.60% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5,504.84B |
| Celltrion | 3,895.99B |
| ALTEOGEN | 202.18B |
| ABL Bio | 88.44B |
| SK Biopharmaceuticals | 675.41B |
| Yuhan | 2,136.67B |
| LigaChem Biosciences | 159.27B |
| Peptron | 6.19B |